Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study

National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA.
Diabetes care (Impact Factor: 8.42). 06/2008; 31(8):1582-4. DOI: 10.2337/dc08-0025
Source: PubMed


We assessed the lifetime risk of cardiovascular disease (CVD) among individuals with and without obesity and diabetes.
Participants were drawn from the original and offspring cohorts of the Framingham Heart Study. Lifetime (30-year) risk of CVD was assessed using a modified Kaplan-Meier approach adjusting for the competing risk of death, beginning from age 50 years.
Over 30 years, the lifetime risk of CVD among women with diabetes was 54.8% among normal-weight women and 78.8% among obese women. Among normal-weight men with diabetes, the lifetime risk of CVD was 78.6%, whereas it was 86.9% among obese men.
The lifetime risk of CVD among individuals with diabetes is high, and this relationship is further accentuated with increasing adiposity.

1 Follower
11 Reads
    • "and, more in general, weight control [29] [30] [31] play a pivotal role in the development CVD complications. On the other hand, nephropathy seems to be related with HbA1c and, more in general, with the glycemic control [32] [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The increasing prevalence of Diabetes and its related complications is raising the need for effective methods to predict patient evolution and for stratifying cohorts in terms of risk of developing diabetes-related complications. In this paper, we present a novel approach to the simulation of a type 1 diabetes population, based on Dynamic Bayesian Networks, which combines literature knowledge with data mining of a rich longitudinal cohort of type 1 diabetes patients, the DCCT/EDIC study. In particular, in our approach we simulate the patient health state and complications through discretized variables. Two types of models are presented, one entirely learned from the data and the other partially driven by literature derived knowledge. The whole cohort is simulated for fifteen years, and the simulation error (i.e. for each variable, the percentage of patients predicted in the wrong state) is calculated every year on independent test data. For each variable, the population predicted in the wrong state is below 10% on both models over time. Furthermore, the distributions of real vs. simulated patients greatly overlap. Thus, the proposed models are viable tools to support decision making in type 1 diabetes. Copyright © 2015. Published by Elsevier Inc.
    Journal of Biomedical Informatics 08/2015; DOI:10.1016/j.jbi.2015.08.021 · 2.19 Impact Factor
  • Source
    • "Cardiovascular disease (CVD) accounts for the majority of morbidity and mortality world-wide. Both are exacerbated by increases in associated risk factors such as obesity, diabetes and hypertension [1]. Causes of cardiac mortality can be divided into two categories: 1) cardiac, which includes both structural components such as heart failure and 2) functional components such as arrhythmogenic (neurologic) causes [2]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Heart rate is dependent on a cycle of depolarization and repolarization of the atria and ventricles that is regulated by intrinsic and extrinsic factors. Inhomogeneity in ventricular repolarization, measured as QT interval dispersion (QTd) is likely to lead to arrhythmia. The role of the autonomic nervous system in the development of this inhomogeneity is still uncertain. Autonomic regulation can be measured using the tone-entropy algorithm, which indicates inter-beat interval variation. When a sliding cut-off for QTd was used only the control group had a significant association between QTd and both tone and entropy. This finding suggests that for certain levels of ventricular inhomogeneity, autonomic control becomes more dissociated from intra-beat variation measured by QTd. This may be an early sign of potentially fatal arrhythmia.
    Computing in Cardiology, 2010; 10/2010
  • Source
    • "Furthermore, the risk of developing CVD dramatically increases when both diabetes and overweight/obesity are present. The coexistence of these 2 comorbidities results in a lifetime risk of between 80% and 90% of development of CVD in women and men, respectively [13]. Nearly 85% of patients with type 2 diabetes are overweight (body mass index [BMI] ≥ 25 kg/m2) and approximately 55% are considered obese (BMI ≥ 30 kg/m2) [14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To summarize data supporting the effects of antidiabetes agents on glucose control and cardiovascular risk factors in patients with type 2 diabetes. Studies reporting on the effects of antidiabetes agents on glycemic control, body weight, lipid levels, and blood pressure parameters are reviewed and summarized for the purpose of selecting optimal therapeutic regimens for patients with type 2 diabetes. National guidelines recommend the aggressive management of cardiovascular risk factors in patients with type 2 diabetes, including weight loss and achieving lipid and blood pressure treatment goals. All antidiabetes pharmacotherapies lower glucose; however, effects on cardiovascular risk factors vary greatly among agents. While thiazolidinediones, sulfonylureas, and insulin are associated with weight gain, dipeptidyl peptidase-4 inhibitors are considered weight neutral and metformin can be weight neutral or associated with a small weight loss. Glucagon-like peptide-1 receptor agonists and amylinomimetics (e.g. pramlintide) result in weight loss. Additionally, metformin, thiazolidinediones, insulin, and glucagon-like peptide-1 receptor agonists have demonstrated beneficial effects on lipid and blood pressure parameters. Management of the cardiovascular risk factors experienced by patients with type 2 diabetes requires a multidisciplinary approach with implementation of treatment strategies to achieve not only glycemic goals but to improve and/or correct the underlying cardiovascular risk factors.
    Cardiovascular Diabetology 08/2010; 9(1):45. DOI:10.1186/1475-2840-9-45 · 4.02 Impact Factor
Show more


11 Reads
Available from